Subscribe
emiliaungur-shutterstock-com
EmiliaUngur / Shutterstock.com
17 August 2015Americas

FFC claims Allergan’s complaint violates anti-SLAPP laws

US hedge fund Ferrum Ferro Capital (FFC) has asked a California court to reject Allergan’s complaint about malicious prosecution because it allegedly violates a state law designed to stop parties from intentionally burdening another party with a legal complaint.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Allergan survives Combigan patent challenge
29 September 2015   Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Allergan survives Combigan patent challenge
29 September 2015   Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review.

More on this story

Americas
Allergan survives Combigan patent challenge
29 September 2015   Pharmaceutical company Allergan has survived an attempt by hedge fund Ferrum Ferro Capital to invalidate a patent covering its Combigan drug after the Patent Trial and Appeal Board opted not to institute an inter partes review.

More features

Takeda loses AMR treatment patent used in kidney transplants
Withers & Rogers hires cell and gene therapy expert
Medtech firm strikes out part of Apple button patent in ECG row
Tissue repair VP gets new trial over secrets damages
Labcorp's bid to invalidate Ravgen's DNA testing patent hits roadblock
Troutman Pepper Locke exodus sees teams leave in Chicago and London
Ex-Baker McKenzie patent litigation head joins Morgan Lewis in Germany
Mitsubishi Tanabe takes on Indian generic drugmaker’s ALS application